US Edition
REGENXBIO AFFINITY DUCHENNE: Trial of Investigational RGX-202 Gene Therapy
Summary by CureDuchenne
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
REGENXBIO AFFINITY DUCHENNE: Trial of Investigational RGX-202 Gene Therapy
In this webinar, Dr. Naz Dastgir, Executive Medical Director and Clinical Development Lead for RGX-202 at REGENXBIO, shared information on the active and enrolling AFFINITY DUCHENNE trial and how families can obtain additional information about RGX-202 and potential clinical trial participation.Watch HEREThe post REGENXBIO AFFINITY DUCHENNE: Trial of Investigational RGX-202 Gene Therapy appeared first on CureDuchenne.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium